Contributions
Abstract: EP1295
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Antibodies to aquaporin-4 (AQP4-Ab) is a sensitive and highly specific serum marker of neuromyelitis optica (NMO) and NMO-spectrum disorders (NMOSD). Area postrema syndrome is the third most frequent after optical neuritis and myelitis in NMOSD. Clinical manifestations of this syndrome include indomitable nausea, vomiting and hiccups, which in most cases persist for several weeks. Frequently the area postrema syndrome is the first clinical manifestation of NMOSD, which significantly complicates proper diagnosis.
Objectives: The aim of our research was to analyze the characteristics of patients with NMOSD according to demographics, clinical symptoms and MRI findings and estimate frequency of AQP4-Ab in Russian group patients with NMOSD.
Methods and patients: Serum samples from 67 neurological patients with NMOSD were analyzed. We used cell-based assay for the detection of AQP4-Ab (Euroimmun).
Results: 67 patients (83% female) aged 16-67 years (mean age 40.2 years) were included in the study. AQP4-Ab were detectable in 89.6% patients with NMOSD. The mean age of onset of symptoms was 35.2 years. The mean time to diagnosis was 20 months (range: 1 month-5 years). In most patients, the onset symptoms were longitudinally extensive transverse myelitis (LETM) and optic neuritis(ON). In total, during disease course 11 patients developed area postrema syndrome and in seven cases, the disease manifested with area postrema syndrome. Time to diagnosis in cases with area postrema syndrome manifestation was higher than LETM and ON manifestation. These patients have been supposed as patients with gastrointestinal pathology or infectious disease at first.
According to MRI, 83% of the patients had LETM lesions and 14% had short transverse myelitis lesions extending fewer than three vertebral segments. Spinal cord lesions spanned 1-13 vertebral segments (mean 5.5). The cervical cord was involved in 30% of cases, thoracic cord - in 30%, both cervical and thoracic cord - in 40%. 19% of patients had brain lesions.
Our results confirm high clinical heterogeneity of NMOSD and specificity of AQP4-Ab as a marker of NMOSD
Disclosure: Name: nothing to disclose
Abstract: EP1295
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Antibodies to aquaporin-4 (AQP4-Ab) is a sensitive and highly specific serum marker of neuromyelitis optica (NMO) and NMO-spectrum disorders (NMOSD). Area postrema syndrome is the third most frequent after optical neuritis and myelitis in NMOSD. Clinical manifestations of this syndrome include indomitable nausea, vomiting and hiccups, which in most cases persist for several weeks. Frequently the area postrema syndrome is the first clinical manifestation of NMOSD, which significantly complicates proper diagnosis.
Objectives: The aim of our research was to analyze the characteristics of patients with NMOSD according to demographics, clinical symptoms and MRI findings and estimate frequency of AQP4-Ab in Russian group patients with NMOSD.
Methods and patients: Serum samples from 67 neurological patients with NMOSD were analyzed. We used cell-based assay for the detection of AQP4-Ab (Euroimmun).
Results: 67 patients (83% female) aged 16-67 years (mean age 40.2 years) were included in the study. AQP4-Ab were detectable in 89.6% patients with NMOSD. The mean age of onset of symptoms was 35.2 years. The mean time to diagnosis was 20 months (range: 1 month-5 years). In most patients, the onset symptoms were longitudinally extensive transverse myelitis (LETM) and optic neuritis(ON). In total, during disease course 11 patients developed area postrema syndrome and in seven cases, the disease manifested with area postrema syndrome. Time to diagnosis in cases with area postrema syndrome manifestation was higher than LETM and ON manifestation. These patients have been supposed as patients with gastrointestinal pathology or infectious disease at first.
According to MRI, 83% of the patients had LETM lesions and 14% had short transverse myelitis lesions extending fewer than three vertebral segments. Spinal cord lesions spanned 1-13 vertebral segments (mean 5.5). The cervical cord was involved in 30% of cases, thoracic cord - in 30%, both cervical and thoracic cord - in 40%. 19% of patients had brain lesions.
Our results confirm high clinical heterogeneity of NMOSD and specificity of AQP4-Ab as a marker of NMOSD
Disclosure: Name: nothing to disclose